Rymphysia

Package leaflet: Information for the user

Rymphysia, 500 mg, powder and solvent for solution for infusion
Rymphysia, 1000 mg, powder and solvent for solution for infusion
human alpha1-proteinase inhibitor
This medicinal product will be subject to additional monitoring. This will allow for rapid
identification of new safety information. Users of this medicine can also help by
reporting any side effects that occur after administration. For information on how to report
side effects – see section 4.
Please read this leaflet carefully before using this medicine, as it contains
important information for the patient.

• Keep this leaflet, as you may need to read it again.
• If you have any further questions, please consult your doctor or healthcare professional.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. This medicine may harm others, even if their symptoms are the same.
• If any side effects occur in the patient, including any side effects not listed in this leaflet, inform your doctor or other healthcare professional. See section 4.

Leaflet contents

1. What Rymphysia is and what it is used for
2. What you need to know before using Rymphysia
3. How to use Rymphysia
4. Possible side effects
5. How to store Rymphysia
6. Contents of the pack and other information

1. What Rymphysia is and what it is used for

What Rymphysia is
This medicine contains the active substance called "human alpha1-proteinase inhibitor", which is a normal
component of blood and is present in the lungs. Its main function in the lungs is to protect lung tissue
by inhibiting the activity of an enzyme called neutrophil elastase. Neutrophil elastase can cause damage
if its activity is not controlled (for example, if the patient has alpha1-proteinase inhibitor deficiency).
Why Rymphysia is used
This medicine is used in adults diagnosed with severe alpha1-proteinase inhibitor deficiency (also known as
alpha1-antitrypsin deficiency) who have developed a lung disease called emphysema.
Emphysema occurs when the lack of alpha1-proteinase inhibitor leads to a condition in which neutrophil elastase
is not properly controlled, causing damage to the small air sacs in the lungs through which oxygen passes into the body.
Due to this damage, the lungs do not function properly.
Regular use of this medicine increases the concentration of alpha1-proteinase inhibitor in the blood and lungs,
thereby protecting the lungs by limiting the activity of neutrophil elastase and thus slowing the progression of emphysema.
It should not be expected that this medicine will reverse damage that has already occurred.

2. Important information before using Rymphysia

When not to use Rymphysia

• if the patient is allergic to "human alpha1-proteinase inhibitor" or to any of the other ingredients of this medicine (listed in section 6),
• if the patient has been diagnosed with a deficiency in blood proteins called immunoglobulin A (IgA) and has antibodies against these immunoglobulins.

If any of the above apply to the patient, Rymphysia must not be used.
Warnings and precautions
Before starting treatment with Rymphysia, discuss this with your doctor or another healthcare professional.
Information about allergic reactions
The patient may be allergic to Rymphysia, even if previously treated with similar medicines and well tolerated.

• In some cases, a severe allergic reaction may occur.
• The doctor will inform the patient about the symptoms of allergic reactions (for example, chills, hot flushes, faster heartbeat, drop in blood pressure, feeling dizzy, rash, hives, itching, difficulty breathing or swallowing, as well as swelling of the hands, face, or mouth) – see also “Allergic reactions” in section 4.
• If the reaction is severe, the doctor may decide to reduce or completely stop the infusion rate. Appropriate treatment for the symptoms of the allergic reaction may then be administered.

Immediately inform the doctor or another healthcare professional if any of the above-mentioned reactions occur during infusion. If treatment is administered at home and/or self-administered, immediately stop the infusion and contact the doctor or another healthcare professional.
Risk of infection
Rymphysia is manufactured from human blood plasma (the fluid component of blood from which blood cells have been removed).
When medicines are made from human blood or plasma, specific precautions are taken to prevent transmission of infections to patients. These include:

• careful selection of blood and plasma donors to ensure exclusion of donors who may carry infections,
• testing of each donated sample and pooled plasma for traces of viruses/infections,
• inclusion of steps in the manufacturing process intended to inactivate or remove viruses.

Nevertheless, despite these precautions, it cannot be completely ruled out that medicines prepared from human blood or plasma may transmit infection, including any unknown or new viruses or other types of infections.
The measures taken are considered effective against enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, as well as non-enveloped viruses such as hepatitis A virus and parvovirus B19.
To improve traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded.
If the patient receives regularly/repeatedly proteinase inhibitors derived from human plasma, the doctor may recommend considering vaccination against hepatitis A and B.
Smoking
Tobacco smoke is an important risk factor for the development and progression of emphysema; therefore, quitting smoking and avoiding passive smoking are strongly recommended.
Children and adolescents
This medicine is not intended for use in children and adolescents under 18 years of age.
Rymphysia with other medicines
Tell your doctor or another healthcare professional about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take. This includes medicines available without a prescription and herbal medicines.
This is necessary because Rymphysia may affect the action of certain other medicines. In addition, some medicines may affect the action of Rymphysia.
Pregnancy, breastfeeding and fertility
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or is planning to have a baby, she should consult her doctor or another healthcare professional before using this medicine.
Since alpha1-proteinase inhibitor is a normal component of human blood, the recommended dose of this medicine is not expected to have harmful effects on the developing fetus.
However, due to the lack of available data on the safety of using Rymphysia during pregnancy, the medicine should be used during pregnancy only with caution.
It is not known whether Rymphysia passes into human milk. If the patient is breastfeeding, the doctor will discuss with her the risks and benefits associated with using this medicine.
There are no data on the effect on fertility; however, since alpha1-proteinase inhibitor is a normal component of human blood, no adverse effect on fertility is expected when Rymphysia is used at the recommended dose.
Driving and operating machinery
Rymphysia may have a minor influence on the ability to drive and operate tools or machinery. If the patient experiences dizziness or fatigue, he or she should not drive or operate tools or machinery.
Rymphysia contains sodium
Rymphysia 500 mg, powder and solvent for solution for infusion:

• The medicine contains 108 mg of sodium (main component of table salt) per 25 ml vial of solution. This corresponds to 5.4% of the maximum recommended daily dietary intake of sodium for adults.

Rymphysia 1000 mg, powder and solvent for solution for infusion:

• The medicine contains 216 mg of sodium (main component of table salt) per 50 ml vial of solution. This corresponds to 10.8% of the maximum recommended daily dietary intake of sodium for adults.

3. How to use Rymphysia

Rymphysia is administered as an intravenous infusion. The first infusions will be supervised by
medical personnel experienced in the treatment of alpha1-proteinase inhibitor deficiency.
Home treatment and (or) self-administration by the patient
After the initial infusions, Rymphysia may be self-administered by the patient or the patient's caregiver,
but only after appropriate training has been completed. If the physician determines that the patient is suitable for home treatment and (or) self-administration, the patient or caregiver will be trained in the following:

• how to prepare and administer this medicine (see instructions at the end of this leaflet),
• how to maintain the medicine in a sterile condition (principles of aseptic infusion techniques),
• how to keep a treatment diary,
• how to recognize adverse reactions, including symptoms of allergic reactions, and what actions should be taken if such reactions occur (see also section 2 and section 4).

The treating physician or another qualified healthcare professional will regularly monitor the patient’s and (or) caregiver’s infusion technique to ensure that the medicine is always correctly prepared and administered.
Dosage
The dose of Rymphysia depends on the patient's body weight. The recommended dose is 60 mg per kg of body weight, to be administered once weekly. The infusion will last approximately 15–30 minutes. The physician will determine the appropriate dose and infusion rate based on the patient's body weight and tolerance to the infusion.
Use of a higher than recommended dose of Rymphysia
If the patient suspects that an overdose of Rymphysia has been administered, they should contact their physician or another qualified healthcare professional immediately, who will decide on the appropriate course of action. The consequences of overdose are unknown.
Missed dose of Rymphysia
If an infusion is missed, the next dose should be administered as soon as possible, and treatment should continue at the regular intervals prescribed by the physician or another qualified healthcare professional.
Do not administer a double dose to make up for a missed dose.
Stopping treatment with Rymphysia
Do not discontinue treatment with this medicine without consulting your physician or another qualified healthcare professional. Discontinuation of treatment with Rymphysia may result in worsening of the patient's condition.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
Such adverse reactions may occur even if the patient has previously received similar medicines
to Rymphysia and tolerated them well. The following adverse reactions may occur with this medicine:

Allergic reactions
Immediately inform your doctor or another healthcare professional
if any of the following severe adverse reactions occur during administration of Rymphysia, as the patient may require immediate medical attention:

• chills or hot flushes,
• faster heartbeat, drop in blood pressure, or feeling dizzy,
• rash, hives, or itching,
• difficulty breathing or swallowing, as well as swelling of the hands, face, or mouth.

Immediately inform your doctor or another healthcare professional
if any of the above severe adverse reactions occur.
If the reaction is severe, the doctor or another healthcare professional may
decide to reduce the infusion rate or stop the infusion completely. They may then administer
appropriate symptomatic treatment for the allergic reaction.
In case of home treatment and/or self-administration, immediately stop the infusion
and contact your doctor or another healthcare professional.

• Allergic reactions are uncommon and may occur in up to 1 in 100 patients.
• Severe allergic reactions are very rare and may occur in up to 1 in 10,000 patients.
• Allergic reactions may occur even if no allergic symptoms were observed during previous infusions.

Other adverse reactions
Immediately inform your doctor or another healthcare professional
if any of the following adverse reactions occur:

Very common: may affect more than 1 in 10 patients

• bronchitis (persistent cough, which may produce mucus, wheezing, difficulty breathing);
• upper respiratory tract infection (common cold, flu-like illness);
• headache;
• cough;
• sore throat (pain in the throat and larynx);

Common: may affect up to 1 in 10 patients

• altered taste sensation (dysgeusia);
• discomfort in the head, migraine;
• drowsiness;
• eye disorders (conjunctivitis, eye irritation, visual disturbances);
• nasal congestion (rhinitis);
• throat irritation;
• bloating, diarrhoea, oral ulceration, vomiting;
• chest pain or discomfort;
• fever and malaise (flu-like illness);
• pain and bruising at the infusion site;
• feeling of extreme fatigue and drowsiness;
• discomfort, pain, or tenderness in muscles (myalgia);
• general feeling of discomfort, illness, or being unwell without a clear cause (malaise);

Frequency not known: frequency cannot be estimated from available data

• feeling of weakness;
• feeling unwell or different than normal;
• reaction at the infusion site, such as bruising, pain, or rash;

Reporting of adverse reactions
If any adverse symptoms occur, including any adverse symptoms not listed
in this leaflet, inform your doctor or another healthcare professional.
Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions at the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorization holder.
Reporting adverse reactions helps to provide more information on the safety of the medicine.

5. How to store Rymphysia

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the outer carton and on the vial label after "EXP". The expiry date refers to the last day of the specified month.
Do not store above 25°C. Do not freeze. Store in the original packaging to protect from light.
After reconstitution, the resulting solution should be used immediately. If this is not possible, the solution may be stored at room temperature (up to 25°C) for up to 3 hours. Do not freeze the prepared solution.

6. Contents of the package and other information

What Rymphysia contains

• The active substance is human alpha1-proteinase inhibitor. One vial contains approximately 500 mg or 1000 mg of human alpha1-proteinase inhibitor.
• Other ingredients: sodium chloride, monosodium dihydrogen phosphate monohydrate, and sodium hydroxide.
• Solvent: sterile water for injections.

What Rymphysia looks like and contents of the pack
Powder and solvent for solution for infusion.
This medicine is a white or off-white to slightly yellow-green or yellow powder.
After reconstitution with sterile water for injections, the solution should be clear, colourless,
or slightly yellow to yellow-green, and should not contain visible solid particles.
One pack contains:
Rymphysia 500 mg, powder and solvent for solution for infusion:

• One vial containing Rymphysia 500 mg powder
• One vial containing 25 ml of sterile water for injections
• One sterile double-ended transfer needle
• One sterile filter with a pore size of 20 microns

Rymphysia 1000 mg, powder and solvent for solution for infusion:

• One vial containing Rymphysia 1000 mg powder
• One vial containing 50 ml of sterile water for injections
• One sterile double-ended transfer needle
• One sterile filter with a pore size of 20 microns

Marketing Authorisation Holder
Takeda Pharma Sp. z o.o.
ul. Prosta 68
00-838 Warsaw
Tel.: +48 22 306 24 47
[email protected]

Manufacturer
Takeda Manufacturing Austria AG
Industriestrasse 67
1221 Vienna
Austria

This medicinal product is authorised for sale in the European Economic Area countries under the following names:
Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Italy, Latvia, Luxembourg, Norway, Poland, Portugal, Romania, Spain, Sweden: Rymphysia

Information intended for healthcare professionals and trained caregivers

and (or) patients:
General instructions

• Rymphysia is intended for intravenous use only.
• Reconstitution, administration, and any manipulations involving the product must be performed with caution and under aseptic conditions to maintain sterility.
• Prior to reconstitution, allow Rymphysia and the diluent to reach room temperature.
• After reconstitution, Rymphysia should be stored at room temperature and administered within three (3) hours of reconstitution. Partially used vials must be discarded and must not be stored for future use. The solution does not contain any preservative.
• Any unused portions of the medicinal product or waste materials should be disposed of in accordance with local regulations.

Reconstitution

1. Remove the caps from the vials containing the diluent and the product.
2. Wipe the exposed stopper surfaces with alcohol.
3. Remove the cover from one end of the double-ended transfer needle. Insert the exposed end of the needle through the center of the diluent vial stopper.
4. Remove the plastic cover from the other end of the transfer needle that is inserted into the diluent vial stopper. To minimize foaming, invert the diluent vial and insert the exposed end of the needle through the center of the product vial stopper at an angle, ensuring that the diluent vial remains above the product vial at all times. Inserting the needle at an angle directs the stream of diluent onto the vial wall. See: figure below. The vacuum in the vial is sufficient to transfer the entire volume of diluent.

5. Disconnect the two vials by removing the diluent vial from the transfer needle. This equalizes any low pressure that may have developed in the product vial. Then remove the double-ended transfer needle from the product vial and discard the needle into an appropriate sharps container.
6. Place the vial upright and allow it to stand until most of the content dissolves, then GENTLY rotate the vial to achieve complete dissolution of the powder. Reconstitution takes no longer than five (5) minutes for the 500 mg vial and no longer than ten (10) minutes for the 1000 mg vial. Caution: Do not shake the vial contents. Do not invert the vial until ready to withdraw the solution.
7. The reconstituted product is colorless or slightly yellow to yellow-green.
8. Occasionally, a few small visible particles may remain in the reconstituted product. These will be removed by the sterile 20-micron pore filter provided with the product.

Administration

1. Prior to administration, inspect the reconstituted product for the presence of particulate matter and discoloration.
2. The contents of multiple vials may be transferred into an empty, sterile intravenous solution container. Use aseptic technique and a sterile needle (not supplied with the product).
3. To minimize the risk of microbial contamination, Rymphysia must be administered within three (3) hours of reconstitution. Any unused portion must be discarded.
4. Rymphysia must be administered separately and must not be mixed with any other agents or diluent solutions.

Infusion rate

• The recommended infusion rate is 0.08 ml/kg body weight per minute. The infusion rate may be adjusted according to clinical response and patient tolerance, but must not exceed 0.2 ml/kg body weight per minute.
• If adverse reactions occur, reduce the infusion rate or stop the infusion. Once symptoms resolve, resume infusion at a rate tolerated by the patient.